NCT02073240 (EnTIC) is a clinical trial of Enhanced TB IC Package in Tuberculosis, sponsored by Centers for Disease Control and Prevention.

Who is sponsoring NCT02073240?

NCT02073240 is sponsored by Centers for Disease Control and Prevention.

What drugs are being tested in NCT02073240?

Interventions in NCT02073240: Enhanced TB IC Package.

What condition does NCT02073240 study?

NCT02073240 studies Tuberculosis.

Is NCT02073240 still recruiting?

NCT02073240 is currently completed. Last updated 2 February 2021.

Last reviewed 2021-02-02 · How we verify

NCT02073240: EnTIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of an Enhanced Tuberculosis Infection Control Intervention in Healthcare Facilities in Vietnam and Thailand

Completed Last updated 2 February 2021

What this trial tests

trial testing Enhanced TB IC Package in Tuberculosis in 22 participants. Completed in 18 November 2016.

Timeline

17 February 2014

Primary endpoint
18 November 2016

18 November 2016

Quick facts

Lead sponsor	Centers for Disease Control and Prevention
Status	Completed
Study type	OBSERVATIONAL
Enrollment	22
Start date	17 February 2014
Primary completion	18 November 2016
Estimated completion	18 November 2016
Sites	22 locations across Thailand, Vietnam

Drugs / interventions tested

Enhanced TB IC Package

Conditions studied

Tuberculosis — all drugs for Tuberculosis →

Sponsor

Centers for Disease Control and Prevention — full company profile →

Who can join

Adults 18 to 45, any sex, with Tuberculosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study Design: Stratified, matched, cluster-randomized, controlled trial Unit of Randomization: Healthcare facility Study Duration: 3 years; prevalence of latent Tuberculosis infection (LTBI) in healthcare workers (HCWs) will be at measured at baseline, and LTBI incidence will be measured among susceptible HCWs at 12 and 24 months. Secondary outcomes will be measures at 0 (pre-intervention) 6, 12, 18, and 24 months. In year three, results will be analyzed and disseminated. Study Components: Assessment of institutional safety culture; observations/audits of Tuberculosis (TB) patient flow (wait times) and HCW TB infection control (IC) practices; documentation of time intervals for processing sputum smears and initiation of TB treatment; facility assessments; random allocation and implementation of enhanced Tuberculosis infection control (TB IC) package; testing of HCWs to determine LTBI at 0, 12, 24 months; cost evaluation of intervention. Sample Size: For the cluster randomized design, we estimate that 11 clusters per group will allow for 77 percent (%) power to identify a 30% reduction in LTBI incidence in the intervention vs. control clusters. This assumes LTBI incidence 5% per year in the control group, design effect for clustering of 2.0, and cluster size of 300 (average 600 HCW per cluster with 50% LTBI prevalence at baseline).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Optimising diagnosis and treatment of tuberculosis infection in community and primary care settings in two urban provinces of Viet Nam: a cohort study.
Vo LNQ, Nguyen VN, Nguyen NTT, Dong TTT, et al · · 2023 · cited 3× · PMID 36759036 · DOI 10.1136/bmjopen-2022-071537

Verify or expand the search:

Other recruiting trials for Tuberculosis

Currently open trials in the same condition.

NCT05917210 — Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda · NA · recruiting
NCT07170735 — Quantitative Measurement of Plasma and Urine MTB Cell-free DNA Level · recruiting
NCT07484490 — Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in Tuberculosis · NA · recruiting
NCT06318416 — Precision Rifampin Trial for Personalized Dosing · Phase 1 · recruiting
NCT07170800 — A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets · Phase 2 · recruiting

Other Centers for Disease Control and Prevention trials

Trials by the same sponsor.

NCT06962904 — CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults · Phase 1 · active not recruiting
NCT06485258 — CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults · Phase 1 · completed
NCT05766267 — Short-course Regimens for the Treatment of Pulmonary Tuberculosis · Phase 2, PHASE3 · active not recruiting
NCT06045923 — Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV · recruiting
NCT06054269 — Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02073240 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centers for Disease Control and Prevention
Last refreshed: 2 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02073240.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing